The popularity of Sildenafil initially sparked a surge for major pharmaceutical companies, however recent developments present a murky outlook for shareholders. Lower-cost competitors are eating into earnings, and persistent litigation add additional difficulty to the equation. While specific companies may still benefit from complementary offeri… Read More